Dr. Dipp is the founding Chief Executive Officer of OvaScience and serves on the Board of Directors. Dr. Dipp is also a Founder and Partner of Longwood Fund, which founds and invests in healthcare companies such as Alnara (acquired by Eli Lilly) and Verastem. Previously, Dr. Dipp was the Senior Vice President and Head of the CEEDD at GlaxoSmithKline. Prior, she was Vice President of Corporate Development at Sirtris, where she led the successful acquisition of Sirtris by GSK for $720 million. Before joining Sirtris as a founding employee, she worked in healthcare private equity at The Wellcome Trust, London. Dr. Dipp serves on the Biotechnology Industry Organization’s (BIO) Emerging Companies Governing Board, the Beth Israel Deaconess Medical Center Board of Trustees, the Boston Symphony Orchestra Board of Overseers, and the MassBio Advisory Board.
Dr. Dipp holds an M.D. and a Ph.D. from the University of Oxford.
Mr. Bleck has more than 25 years of successful senior management experience in the medical device, diagnostic and pharmaceutical industries. For the last 10 years, Mr. Bleck has worked exclusively in women's healthcare. Most recently, he served as President & CEO of Incept BioSystems, where he lead the product and clinical development of a micro-fluidic culture system designed to improve the quality of human embryos. The Incept technology platform was acquired by Origio a/s, a leader in Assisted Reproductive Technology (ART) solutions. Prior to Incept, Mr. Bleck served as President and CEO of Intact Medical Corporation. Intact Medical manufactured a breast biopsy and tissue excision system used in the diagnosis and treatment of breast cancer. Mr. Bleck had previously served as Vice President of Commercial Operations for Cytyc Corporation, a diagnostic and therapeutic medical device company focused on women’s health. Mr. Bleck’s history also includes 18 years in senior management at Abbott Laboratories, including positions as Corporate Vice President, Pediatric Products and President & General Manager, Abbott Canada.
Mr. Bleck holds a B.S. degree in Pharmacy and an M.B.A. from The University of Connecticut.
Dr. Tzianabos brings to OvaScience more than 20 years of experience in drug discovery and development, strategic planning, portfolio management, business development and alliance management. He joins OvaScience from Shire, where he most recently served as Senior Vice President and Head, Research and Early Development. During his eight years at Shire, he served in roles of increasing responsibility and was instrumental in the development of the human genetic therapies pipeline following Shire’s acquisition of Transkaryotic Therapies, Inc. in 2005. Prior to Shire, Dr. Tzianabos was an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. His research at Harvard led to the discovery of a new class of immunoregulatory, T cell-dependent antigens, which formed the basis for technologies licensed by two biotechnology companies and Eli Lilly and Company for clinical development. During his time at Harvard, he served as a consultant to several biotechnology companies, including Genzyme Corporation and Eli Lilly. Dr. Tzianabos has published more than 80 scientific papers, book chapters and patents in the field of immunology, glycobiology and infectious disease, and was on the Board of Directors of bluebird bio and ArmaGen Technologies.
He holds a B.S. in biology from Boston College and a Ph.D. in microbiology from the University of New Hampshire.
Ms. Lawton has more than 28 years of global pharmaceutical and biotechnology experience, including 21 years at Genzyme Corporation and seven years in the U.K. at Warner-Lambert/Parke-Davis. Prior to OvaScience, she was Senior Vice President and General Manager at Sanofi Biosurgery (formerly Genzyme Biosurgery), where she was responsible for three separate franchises, including surgical, cell therapy and regenerative medicine, and orthopedics. Prior to Genzyme Biosurgery, Ms. Lawton was Senior Vice President of Global Market Access for Genzyme, which involved leadership across several of Genzyme's global functional organizations including regulatory affairs and corporate quality systems, policy programs, health outcomes and strategic pricing, patient safety and risk management, and biomedical process excellence and training. She served two terms as the industry representative on the U.S. Food and Drug Administration (FDA) Cell & Gene Therapy Advisory Panel, and was past President and Chair of Board of RAPS (Regulatory Affairs Professional Society). Ms. Lawton is currently a Board member of Cubist Pharmaceuticals and Verastem, Inc.
Ms. Lawton holds a B.Sc. Hons. in Pharmacology from King's College London.